Abstract
A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Hepatology (Baltimore, Md.) |
| Vol/bind | 69 |
| Udgave nummer | 5 |
| Sider (fra-til) | 2300 |
| ISSN | 0270-9139 |
| DOI | |
| Status | Udgivet - 2019 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Response to AASLD editorial/message from the president'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS